Scroll

danazol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	779	17230-88-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: danazol chronogyn danatrol danazolum danocrine danovaol danzol winobanin	A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. Molecular weight: 337.46 Formula: C22H27NO2 CLOGP: 3.75 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 46.26 ALOGS: -4.28 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

danazol
chronogyn
danatrol
danazolum
danocrine
danovaol
danzol
winobanin

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.

Molecular weight: 337.46
Formula: C22H27NO2
CLOGP: 3.75
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.26
ALOGS: -4.28
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	33.78 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	5.18 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	15.71 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.31 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 21, 1976	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hereditary angioedema	137.11	21.44	33	1765	5409	50597917
Platelet count decreased	58.08	21.44	39	1759	100687	50502639
Hypoperfusion	33.12	21.44	8	1790	1322	50602004
Bone marrow reticulin fibrosis	29.40	21.44	5	1793	140	50603186
Myelofibrosis	24.00	21.44	6	1792	1141	50602185
Therapeutic response decreased	21.81	21.44	16	1782	47215	50556111

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coombs positive haemolytic anaemia	180.93	25.38	33	1972	719	29571803
Lymphadenitis	155.92	25.38	33	1972	1574	29570948
Haemolysis	134.04	25.38	39	1966	6917	29565605
Hereditary angioedema	105.35	25.38	21	1984	740	29571782
Migraine	89.14	25.38	33	1972	12397	29560125
Myelofibrosis	70.63	25.38	17	1988	1445	29571077
Hepatic enzyme increased	68.52	25.38	37	1968	33762	29538760
Infusion related reaction	67.26	25.38	40	1965	43846	29528676
Therapeutic product effect decreased	56.23	25.38	31	1974	29420	29543102
Myelodysplastic syndrome	49.11	25.38	24	1981	17770	29554752
Rhabdomyolysis	44.22	25.38	35	1970	60773	29511749
Drug ineffective	37.29	25.38	78	1927	363092	29209430
Constipation	37.07	25.38	42	1963	114118	29458404
Bone marrow reticulin fibrosis	31.55	25.38	6	1999	164	29572358
Therapeutic response decreased	31.35	25.38	20	1985	24691	29547831
Platelet count decreased	29.77	25.38	36	1969	104636	29467886
Cushingoid	27.16	25.38	9	1996	2429	29570093
Neutropenia	26.18	25.38	38	1967	131673	29440849

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coombs positive haemolytic anaemia	184.62	21.56	33	3304	845	64494550
Hereditary angioedema	156.46	21.56	37	3300	3839	64491556
Lymphadenitis	136.55	21.56	33	3304	3752	64491643
Haemolysis	113.93	21.56	36	3301	11003	64484392
Rhabdomyolysis	68.10	21.56	48	3289	91678	64403717
Myelofibrosis	63.33	21.56	16	3321	2177	64493218
Platelet count decreased	63.16	21.56	59	3278	167652	64327743
Migraine	56.49	21.56	37	3300	62640	64432755
Bone marrow reticulin fibrosis	48.91	21.56	9	3328	271	64495124
Myelodysplastic syndrome	45.25	21.56	24	3313	27555	64467840
Hepatic enzyme increased	41.86	21.56	42	3295	129901	64365494
Immune thrombocytopenia	36.22	21.56	17	3320	15049	64480346
Infusion related reaction	32.14	21.56	41	3296	164426	64330969
Cushingoid	29.43	21.56	12	3325	7591	64487804
Therapeutic product effect decreased	27.81	21.56	32	3305	115319	64380076
Mucosal haemorrhage	25.86	21.56	8	3329	2273	64493122
Hypoperfusion	25.64	21.56	8	3329	2338	64493057
Gingival bleeding	24.56	21.56	13	3324	14841	64480554
Constipation	24.38	21.56	43	3294	229294	64266101
Therapeutic response decreased	22.79	21.56	20	3317	52168	64443227
Non-cirrhotic portal hypertension	22.52	21.56	5	3332	390	64495005
Splenomegaly	22.25	21.56	13	3324	17948	64477447
Drug ineffective	21.57	21.56	93	3244	840154	63655241

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03XA01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Antigonadotropins and similar agents
FDA CS	M0001109	Androstanes
FDA MoA	N0000000146	Androgen Receptor Agonists
CHEBI has role	CHEBI:50751	anti-estrogenic drug
CHEBI has role	CHEBI:50837	oestrogen antagonist
CHEBI has role	CHEBI:176497	geroprotectors
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D006727	Hormone Antagonists
FDA EPC	N0000175824	Androgen

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Fibrocystic breast changes	indication	27431007	DOID:10354
Endometriosis	indication	129103003
Hereditary Angioedema Prevention	indication
Gynecomastia	off-label use	4754008	DOID:12698
Menorrhagia	off-label use	386692008
Precocious puberty	off-label use	400179000
Migraine	contraindication	37796009	DOID:6364
Chronic heart failure	contraindication	48447003
Intermenstrual bleeding - irregular	contraindication	64996003
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Mixed hyperlipidemia	contraindication	267434003
Pregnancy, function	contraindication	289908002
Thromboembolic disorder	contraindication	371039008
Breastfeeding (mother)	contraindication	413712001
Porphyria	contraindication	418470004
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	AGONIST			UNKNOWN	CHEMBL
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN	AGONIST			WOMBAT-PK	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.16	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.09	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.25	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.60	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	4.98	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.01	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.43	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	5.71	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	4.89	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	5.46	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.27	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.20	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.21	DRUG MATRIX
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN		Ki	5.29	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.52	DRUG MATRIX
Steryl-sulfatase	Enzyme	P08842	STS_HUMAN				WOMBAT-PK
Sex hormone-binding globulin	Secreted	P04278	SHBG_HUMAN		Kd	8.20	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.05	DRUG MATRIX
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	5.24	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	4.99	DRUG MATRIX
Androgen receptor	Transcription factor		ANDR_RAT		Ki	8.10	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	7.47	DRUG MATRIX

External reference:

ID	Source
4018233	VUID
N0000146564	NUI
D00289	KEGG_DRUG
258343	RXNORM
4018233	VANDF
C0010961	UMLSCUI
CHEBI:4315	CHEBI
QA1	PDB_CHEM_ID
CHEMBL1479	ChEMBL_ID
DB01406	DRUGBANK_ID
D003613	MESH_DESCRIPTOR_UI
28417	PUBCHEM_CID
6942	IUPHAR_LIGAND_ID
2556	INN_ID
N29QWW3BUO	UNII
3093	MMSL
4533	MMSL
605	MMSL
d00204	MMSL
002116	NDDF
126124009	SNOMEDCT_US
87881000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1368	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1369	CAPSULE	200 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1392	CAPSULE	50 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0633	CAPSULE	50 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0634	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0635	CAPSULE	200 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	42291-243	CAPSULE	200 mg	ORAL	ANDA	16 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	68151-2298	CAPSULE	200 mg	ORAL	ANDA	21 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	71205-861	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	71205-862	CAPSULE	200 mg	ORAL	ANDA	17 sections